SR

Shivji Rawat

Director Director DIN 08837782
DIN 08837782 First appointment Aug 2020 Primary industry Chemicals
Unlock full profile Investments Β· shareholding Β· contact details
Past companies 2 historical roles
Total affiliations 2 Since Aug 2020
Shareholding value β€’β€’β€’β€’ Premium profile

About Shivji Rawat

Data last updated:

Shivji Rawat was a Director at Eupid Pharmaceuticals Private Limited (2021) and Director at Styron Pharmaceuticals Private Limited (2020–2021). The companies operate in Chemicals.

DIN 08837782
Primary Designation Director
Industry Chemicals
First Appointment 18 Aug 2020

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director25 Jun 20212021₹6.9 Lakh (FY 2025)Active
Director18 Aug 20202020₹31.3 Lakh (FY 2025)Active

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Eupid Pharmaceuticals Private Limited
Styron Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Shivji Rawat

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Shivji Rawat

Shivji Rawat was first appointed on 18 Aug 2020 as Director at Styron Pharmaceuticals Private Limited. The most recent appointment on record is 25 Jun 2021 at Eupid Pharmaceuticals Private Limited.

Shivji Rawat held 2 earlier board appointments: Eupid Pharmaceuticals Private Limited (Director, 25 Jun 2021 to 26 Jun 2021); Styron Pharmaceuticals Private Limited (Director, 18 Aug 2020 to 26 Aug 2021).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available